Literature DB >> 28054182

Takotsubo cardiomyopathy: FDG myocardial uptake pattern in fasting patients. Comparison of PET/CT, SPECT, and ECHO results.

Malgorzata Kobylecka1, Monika Budnik2, Janusz Kochanowski3, Radoslaw Piatkowski3, Marek Chojnowski1, Katarzyna Fronczewska-Wieniawska1, Tomasz Mazurek3, Joanna Maczewska1, Michał Peller3, Grzegorz Opolski3, Leszek Krolicki1.   

Abstract

BACKGROUND: The aim of this study was to assess the accumulation pattern of 18F-FDG in fasting patients with takotsubo cardiomyopathy (TTC) and to correlate the results with perfusion scintigraphy and echocardiography.
METHODS: 18 consecutive patients with TTC were identified by clinical symptoms, cardiac catheterization, and echocardiography. Coronary angiography (CA) and transthoracic echocardiography (TTE) were performed on the day of the onset of symptoms. An assessment of myocardial perfusion (99mTc-MIBI) and glucose metabolism (18F-FDG) was performed within 18 days.
RESULTS: SPECT showed no regional perfusion abnormalities in 10/18 patients, and a mild perfusion defect was found in 8/18 patients. Perfusion abnormalities were limited to apical and para-apical regions. In 8/18 cases, there was an increased selective apical 18F-FDG accumulation. In 10/18 cases, in spite of the fastened 18F-FDG protocol, slightly inhomogeneous 18F-FDG uptake was present in the entire myocardium: with relatively reduced uptake of 18F-FDG in the apical region and LV mid-segments.
CONCLUSION: This study demonstrated the heterogeneous nature of myocardial 18F-FDG accumulation in patients with TTC. Selective, preferential apical 18F-FDG uptake in almost half of the patients confirms an existing disorder of glucose metabolism, similar to that observed in stunned or hibernated myocardium.

Entities:  

Keywords:  PET; SPECT apical ballooning nuclear imaging; Takotsubo cardiomyopathy; molecular imaging viability; radioisotopes

Mesh:

Substances:

Year:  2017        PMID: 28054182     DOI: 10.1007/s12350-016-0775-x

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  22 in total

1.  Coronary microvascular abnormality in the reversible systolic dysfunction observed after noncardiac disease.

Authors:  K Sadamatsu; H Tashiro; N Maehira; K Yamamoto
Journal:  Jpn Circ J       Date:  2000-10

2.  Metabolic evidence of myocardial stunning in takotsubo cardiomyopathy: a positron emission tomography study.

Authors:  Kotaro Obunai; Deepika Misra; Andrew Van Tosh; Steven R Bergmann
Journal:  J Nucl Cardiol       Date:  2005 Nov-Dec       Impact factor: 5.952

3.  Reversible inverse mismatch in transient left ventricular apical ballooning: perfusion/metabolism positron emission tomography imaging.

Authors:  Mauro Feola; Gian Luca Rosso; Flavia Casasso; Luisa Morena; Alberto Biggi; Stephane Chauvie; Flavio Ribichini; Eugenio Uslenghi
Journal:  J Nucl Cardiol       Date:  2006-07       Impact factor: 5.952

4.  Cardiac ⁹⁹mTc sestamibi SPECT and ¹⁸F FDG PET as viability markers in Takotsubo cardiomyopathy.

Authors:  Thomas Emil Christensen; Lia Evi Bang; Lene Holmvang; Adam Ali Ghotbi; Martin Lyngby Lassen; Flemming Andersen; Nikolaj Ihlemann; Hedvig Andersson; Peer Grande; Andreas Kjaer; Philip Hasbak
Journal:  Int J Cardiovasc Imaging       Date:  2014-05-23       Impact factor: 2.357

5.  Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function.

Authors:  P A Kaufmann; T Gnecchi-Ruscone; M di Terlizzi; K P Schäfers; T F Lüscher; P G Camici
Journal:  Circulation       Date:  2000-09-12       Impact factor: 29.690

6.  Acute impairment of regional myocardial glucose uptake in the apical ballooning (takotsubo) syndrome.

Authors:  Kevin A Bybee; Joseph Murphy; Abhiram Prasad; R Scott Wright; Amir Lerman; Charanjit S Rihal; Panithaya Chareonthaitawee
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

Review 7.  Ischaemic memory imaging using metabolic radiopharmaceuticals: overview of clinical settings and ongoing investigations.

Authors:  Keiichiro Yoshinaga; Masanao Naya; Tohru Shiga; Eriko Suzuki; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-12       Impact factor: 9.236

8.  Reversible left ventricular systolic dysfunction--reversibility of coronary microvascular abnormality.

Authors:  J Ako; K Takenaka; K Uno; F Nakamura; T Shoji; K Iijima; Y Ohike; S Kim; T Watanabe; M Yoshizumi; Y Ouchi
Journal:  Jpn Heart J       Date:  2001-05

Review 9.  Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction.

Authors:  Abhiram Prasad; Amir Lerman; Charanjit S Rihal
Journal:  Am Heart J       Date:  2008-01-31       Impact factor: 4.749

10.  EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision.

Authors:  Hein J Verberne; Wanda Acampa; Constantinos Anagnostopoulos; Jim Ballinger; Frank Bengel; Pieter De Bondt; Ronny R Buechel; Alberto Cuocolo; Berthe L F van Eck-Smit; Albert Flotats; Marcus Hacker; Cecilia Hindorf; Philip A Kaufmann; Oliver Lindner; Michael Ljungberg; Markus Lonsdale; Alain Manrique; David Minarik; Arthur J H A Scholte; Riemer H J A Slart; Elin Trägårdh; Tim C de Wit; Birger Hesse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-21       Impact factor: 9.236

View more
  3 in total

Review 1.  The role of multimodality imaging in takotsubo cardiomyopathy.

Authors:  Osamu Manabe; Masanao Naya; Noriko Oyama-Manabe; Kazuhiro Koyanagawa; Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2018-06-01       Impact factor: 5.952

2.  Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2018. Part 1 of 2: Positron emission tomography, computed tomography, and magnetic resonance.

Authors:  Wael A AlJaroudi; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2019-01-02       Impact factor: 5.952

Review 3.  Coronary blood flow in heart failure: cause, consequence and bystander.

Authors:  Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2022-01-13       Impact factor: 12.416

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.